Broken Blood Vessels May Drive Alzheimer’s Decline

TL;DR: A new study reveals that impaired cerebrovascular function—the brain’s ability to regulate blood flow—correlates strongly with Alzheimer’s symptoms, offering a potential non-invasive way to detect early cognitive decline. Alzheimer’s disease has long been framed as a problem of toxic protein accumulation: amyloid plaques and tau tangles strangling neurons into silence. But what if the …

Read more

Metformin’s Hidden Brain Mechanism: How the Hypothalamus Controls Blood Sugar

TL;DR: Metformin’s glucose-lowering effect depends on a brain signaling pathway—it inhibits Rap1 in the hypothalamus, activating neurons that tell the liver to stop overproducing glucose. For decades, metformin has been the first-line drug for type 2 diabetes, working so reliably that millions take it daily. Yet its precise mechanism—how it actually lowers blood sugar—has remained …

Read more

How the Brain Hijacks Balance Control in Parkinson’s Disease

TL;DR: When older adults face large balance challenges, their brains shift from relying on quick brainstem reflexes to slower cortical circuits—a shift that happens even in Parkinson’s disease, revealing a mechanistic window into age-related balance loss. Balance isn’t automatic. When you stumble forward or feel the ground shift, your nervous system launches a cascade of …

Read more

How Lecanemab Clears Amyloid: The Microglia & SPP1 Mechanism

TL;DR: Lecanemab, the first Alzheimer’s antibody to slow cognitive decline, works by activating immune cells called microglia through a specific immune signaling pathway, with the molecule SPP1/osteopontin playing a critical role in triggering the brain’s own cleanup machinery. When lecanemab was approved by the FDA, it sparked hope but also raised a fundamental question: how …

Read more

Cell-Type Gene Networks Reveal Hidden Causes of Alzheimer’s

TL;DR: Researchers mapped how genes are regulated differently across six brain cell types in Alzheimer’s disease, discovering that excitatory neurons drive the most extensive regulatory disruptions—and identifying key hub genes like RPS27A that could become therapeutic targets. Alzheimer’s disease is a disease of broken communication. The brain doesn’t just lose cells—it loses control, as genes …

Read more

Chlorpyrifos Pesticide Linked to 2.5x Risk of Parkinson’s Disease

TL;DR: A pesticide sprayed on US crops decades ago more than doubles your risk of Parkinson’s disease, and new research shows exactly how it damages dopamine neurons. You probably never heard of chlorpyrifos, but your neighborhood may have been sprayed with it. This common agricultural insecticide was applied to millions of acres across California and …

Read more

How FP802 Targets the NMDAR/TRPM4 Death Complex to Reverse Alzheimer’s

TL;DR: Researchers discovered a toxic interaction between two brain proteins—NMDAR and TRPM4—that drives neurodegeneration in Alzheimer’s disease, and a small molecule called FP802 that blocks this “death complex” and prevents cognitive decline in mice. Alzheimer’s disease devastates the brain through multiple pathways, but the exact triggering mechanisms remain frustratingly unclear. A new study in Molecular …

Read more

How Ketamine Rewires AMPA Receptors to Treat Depression: Molecular Observation in Humans

TL;DR: Using PET imaging to directly visualize AMPA receptors in the living human brain, researchers discovered that ketamine’s rapid antidepressant effect works by reshuffling these receptors across specific brain regions in patients with treatment-resistant depression — and where they go predicts who will respond to the drug. Nearly one in three people with depression fail …

Read more

How Nitric Oxide Damages TSC2 to Drive Autism Behaviors via mTOR

TL;DR: A chemical messenger called nitric oxide triggers protein damage that sends the mTOR pathway into overdrive in autism-related mouse models, driving social deficits and repetitive behaviors—and blocking this mechanism reverses both the molecular dysfunction and autistic-like behaviors. Autism spectrum disorder involves dozens of genetic variants, yet many converge on a single pathway: mTOR, a …

Read more

How Blocking DUSP6 Extends Ketamine’s Antidepressant Effect to Months

TL;DR: Blocking DUSP6 protein alongside ketamine extends antidepressant effects from 2 weeks to 4+ weeks in mice, potentially offering single-dose treatment instead of repeated infusions. Ketamine works like almost nothing else in psychiatry. A single infusion can lift severe depression within hours, even in patients who’ve failed every other drug. The problem? The magic doesn’t …

Read more